Identification of H2-Db and HLA-A2 Specific CD8 Epitopes from Human KDR/VEGFR-2 that Inhibit Angiogenesis by Vaccination
Description of Invention:
Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2/KDR) is a promising target for cancer therapy due to its critical role in tumor associated angiogenesis and vascularization. This invention describes the amino acid sequences of seven short peptides based upon epitopes of human Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) that bind human Histocompatibility Leukocyte Antigen A2 (HLA-A2). These peptides can potentially induce Cytotoxic T Lymphocyte (CTL)-mediated lysis of tumor vascularization and inhibit tumor growth. The inventors have demonstrated the principles described in this invention in vivo in mice for VEGFR-2, using murine H2-Db specific peptides instead of HLA-A2. This invention has the potential to inhibit angiogenesis and may be applicable to tumor and autoimmune disease therapy.
Inventors:
Drs. Samir Khleif and Yujun Dong (NCI)
Patent Status:
DHHS Reference No. E-158-2005/0-US-01 -- U.S. Provisional Application No. 60/671,867 filed 15 Apr 2005 Licensing Status:
In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
Portfolios: Cancer
Cancer -Therapeutics-Vaccines Cancer -Therapeutics
For Additional Information Please Contact: John Stansberry Ph.D.
NIH Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-5236
Email: stansbej@mail.nih.gov
Fax: (301) 402-0220
